# Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

> **NCT01180764** · PHASE4 · WITHDRAWN · sponsor: **University of Utah**

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Lovaza (Omega-3 acid ethyl esters)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01180764
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn for administrative reasons.
- **Last updated:** 2016-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01180764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01180764, "Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01180764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*